Novel fatty acyl apoE mimetic peptides have increased potency to reduce plasma cholesterol in mice and macaques
| Autor: | Susan E. Appt, Eric M. Morrel, Geeta Datta, David W. Garber, Dennis I. Goldberg, Mayakonda N. Palgunachari, C. Roger White, Gattadahalli M. Anantharamaiah, Thomas C. Register |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
0301 basic medicine Apolipoprotein E Single administration Myristic acid Peptide QD415-436 030204 cardiovascular system & hematology Pharmacology Biochemistry Mice 03 medical and health sciences chemistry.chemical_compound Apolipoproteins E 0302 clinical medicine Endocrinology Plasma cholesterol medicine Animals Humans Potency Chromatography High Pressure Liquid Research Articles apolipoprotein E Electrophoresis Agar Gel Mice Knockout chemistry.chemical_classification dyslipidemia Cholesterol LDL Haplorhini Cell Biology Lipid Metabolism medicine.disease 3. Good health lipoproteins Cholesterol 030104 developmental biology chemistry Low-density lipoprotein peptides Intercellular Signaling Peptides and Proteins Macaca Female lipids (amino acids peptides and proteins) low density lipoprotein Dyslipidemia |
| Zdroj: | Journal of Lipid Research, Vol 59, Iss 11, Pp 2075-2083 (2018) Journal of Lipid Research |
| ISSN: | 0022-2275 |
| DOI: | 10.1194/jlr.m085985 |
| Popis: | Ac-hE18A-NH2 is a dual-domain apoE mimetic peptide that possesses the putative receptor binding domain from apoE (LRKLRKRLLR, denoted hE; residues 141–150) covalently attached to lipid-associating peptide 18A. Like apoE, Ac-hE18A-NH2 reduces plasma cholesterol in animal models and exhibits anti-inflammatory properties independent of its cholesterol-reducing effect. Ac-hE18A-NH2 has already undergone phase I clinical trials as a lipid-lowering agent. To explore the therapeutic potential more, we designed and synthesized new analogues by linking ɑ-aminohexanoic acid, octanoic acid, or myristic acid to LRRLRRRLLR-18A-NH2 ([R]hE18A-NH2) and examined the cholesterol-lowering potency in animals. The modified peptides effectively reduced plasma cholesterol in apoE-null mice fed standard chow or a Western diet; the myristyl analogue was the most effective. A single administration of the myristyl analogue reduced plasma total and LDL cholesterol in a dose-dependent manner in hypercholesterolemic cynomolgus macaques for up to 1 week despite the continuation of a cholesterol-supplemented diet. The myristyl peptide (7.4 mg/kg) reduced total and LDL cholesterol at 24 h by 64% and 74%, respectively; plasma HDL levels were modestly reduced and returned to baseline by day 7. These new analogues should exhibit enhanced potency at lower doses than Ac-hE18A-NH2, which may make them attractive therapeutic candidates for clinical trials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|